|

Restoration of Hypoglycemia Awareness With Metoclopramide

RECRUITINGPhase 2Sponsored by Simon Fisher
Actively Recruiting
PhasePhase 2
SponsorSimon Fisher
Started2019-05-28
Est. completion2026-06-30
Eligibility
Age20 Years – 60 Years
Healthy vol.Accepted
Locations2 sites

Summary

Metoclopramide is a drug approved by the FDA for gastroesophageal reflux and to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. The objective of this study is to determine whether metoclopramide can improve hypoglycemia awareness and decrease the incidence of hypoglycemia in type 1 diabetes patients with hypoglycemia unawareness.

Eligibility

Age: 20 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* Subjects with Type 1 Diabetes Mellitus
* Diabetes duration \> 5 years
* Hemoglobin A1c ≤ 9%
* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines

Exclusion Criteria:

* History of myocardial infarction, cardiac arrhythmia, congestive heart failure and coronary artery insufficiency
* History of stroke or brain disease
* History of genitourinary obstruction or urinary retention
* Advanced liver disease
* Active anemia with hemoglobin less than 11 g/dL
* Female in pregnancy or breastfeeding, or not able to practice effective contraception during the study period
* Uncontrolled mania or active major depressive disorder
* Previous allergic reaction or side effect to heparin use
* Contraindications to metoclopramide or conditions raising the risk for complication development to metoclopramide, such as hypersensitivity to metoclopramide, ongoing mechanical gastrointestinal obstruction, uncontrolled hypertension, pheochromocytoma, seizure disorders, Parkinson's disease, use of neuroleptics or antipsychotics within 6 months, use of benzodiazepines within the last month, active or recent (last 14 days) use of monoamine oxidase inhibitors or opioids, active alcohol or drug abuse, or other sedatives
* Participation in another study evaluating treatment for impaired awareness of hypoglycemia or hypoglycemia-associated autonomic failure in the last 30 days
* Current use of unblinded real-time Continuous Glucose Monitoring System
* Frequent need of acetaminophen administration

Conditions2

DiabetesHypoglycemia Unawareness

Locations2 sites

Kentucky

1 site
University of Kentucky
Lexington, Kentucky, 40516
Simon Fisher, MD, PhD859-562-0473Simon.Fisher@uky.edu

Utah

1 site
University of Utah
Salt Lake City, Utah, 84132

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.